Incidence and type of cancer following the use of OKT3: a single center experience with 557 organ transplants.
Batiuk
T D
TD
Laboratory of Immunogenetics and Transplantation, Oregon Health Sciences University, Portland 97201.
Barry
J M
JM
Bennett
W M
WM
Meyer
M M
MM
Tolzman
D
D
Norman
D J
DJ
D002759:Adenoma, Bile Duct / Q000453:epidemiology; D000367:Age Factors; D001379:Azathioprine / Q000627:therapeutic use; D016572:Cyclosporine / Q000627:therapeutic use; D005500:Follow-Up Studies; D006801:Humans; D007165:Immunosuppression Therapy / Q000009:adverse effects*; D015994:Incidence; D016030:Kidney Transplantation / Q000276:immunology*; D008223:Lymphoma / Q000453:epidemiology; D008297:Male; D016853:Muromonab-CD3 / Q000009:adverse effects* / Q000627:therapeutic use; D009369:Neoplasms / Q000453:epidemiology*; D011471:Prostatic Neoplasms / Q000453:epidemiology; D012189:Retrospective Studies; D012878:Skin Neoplasms / Q000453:epidemiology; D013964:Thyroid Neoplasms / Q000453:epidemiology
D016853:Muromonab-CD3; D016572:Cyclosporine; D001379:Azathioprine